Chairman of Morningside Pharmaceuticals, Dr Nik Kotecha OBE, looks at how international accreditation may help companies protect their supply chains.
As the old adage goes ‘trouble comes in threes’, which is certainly the case for UK business this winter.
Not only will there be significant disruption at the end of the Transition Period, with or without a deal with the EU; UK PLC also has the second wave of Covid-19 to contend with, as well as the renewed threat of a double-dip recession.
These three troubles will most acutely be felt by UK businesses, which rely on sophisticated supply chains to import and export their goods with the EU and the rest of the world.
There is a wide range of advice from the government for preparing for the end of the Transition Period, which businesses should go through in detail and act upon immediately, as we hurtle towards the 31 December deadline.
At Morningside Pharmaceuticals, which manufactures and supplies a wide range of quality generic medicines for the UK and international export markets, we have been prepari
Exclusive My CBI member-only content 
